At AM-Pharma we work together in a constructive, collaborative and team-oriented way, towards achieving the company objectives without losing sight of our own objectives. We put the common interest of the patients and the company above our own individual interest.
AM-Pharma’s purpose is to save and improve the lives of patients confronted with severe medical conditions. Our focus is on cardiac surgery-associated renal damage (CSA-RD), which occurrs in 40% of all cardiac surgeries. Our proprietary compound, ilofotase alfa, has a demonstrated safety profile and showed reno-protective effects in global clinical trials involving over 1,000 subjects. In addition, based on preclinical data showing improved overall survival and restored phenotypes associated with hypophosphatasia (HPP), as well as a biomarker dose response in adult patients with HPP treated with ilofotase alfa, we are developing ilofotase alfa as a potential enzyme replacement therapy in HPP. We are a dedicated team driven to bring treatment options to severely ill patients, their families and health care professionals.
AM-Pharma is a clinical stage biopharmaceutical company based in Utrecht, the Netherlands.
AM-Pharma, founded in 2001 and based in Utrecht, the Netherlands, is developing its proprietary recombinant human alkaline phosphatase therapeutic, ilofotase alfa, for treatment of CSA-RD and HPP.
INTERESTED IN A CAREER AT AM-PHARMA?
Details of current vacancies – if any – are listed on this page. To apply, please send your CV and cover letter, stating the title of the position you are applying for, to email@example.com.